Stefan Rutkowski
Prof. Dr. med.
Stefan Rutkowski
  • Klinikdirektor
  • Facharzt für Kinder- und Jugendmedizin, Schwerpunkt Kinder-Hämatologie und - Onkologie
Arbeitsbereich

Standort

O45 , 1. Etage, Raumnummer 01.5.044.1
Sprachen
Deutsch (Muttersprache)
Spanisch
Englisch

Fachgebiete

Tätigkeitsschwerpunkte

Lebenslauf

Mitgliedschaften

Publikationen

2024

Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation
Neyazi S, Yamazawa E, Hack K, Tanaka S, Nagae G, Kresbach C, Umeda T, Eckhardt A, Tatsuno K, Pohl L, Hana T, Bockmayr M, Kim P, Dorostkar M, Takami T, Obrecht D, Takai K, Suwala A, Komori T, Godbole S, Wefers A, Otani R, Neumann J, Higuchi F, Schweizer L, Nakanishi Y, Monoranu C, Takami H, Engertsberger L, Yamada K, Ruf V, Nomura M, Mohme T, Mukasa A, Herms J, Takayanagi S, Mynarek M, Matsuura R, Lamszus K, Ishii K, Kluwe L, Imai H, von Deimling A, Koike T, Benesch M, Kushihara Y, Snuderl M, Nambu S, Frank S, Omura T, Hagel C, Kugasawa K, Mautner V, Ichimura K, Rutkowski S, Aburatani H, Saito N, Schüller U
ACTA NEUROPATHOL. 2024;147(1):22.

And what about today?: Burden and support needs of adolescent childhood cancer survivors in long-term follow-up care-A qualitative content analysis
Winzig J, Inhestern L, Sigmund D, Paul V, Hail L, Rutkowski S, Escherich G, Bergelt C
CHILD CARE HLTH DEV. 2024;50(1):e13207.

2023

Integrated proteomics spotlight the proteasome as a therapeutic vulnerability in Embryonal Tumors with Multilayered Rosettes
Dottermusch M, Biabani A, Lempertz T, Schumann Y, Navolic J, Godbole S, Obrecht D, Frank S, Dorostkar M, Voß H, Schlüter H, Rutkowski S, Schüller U, Neumann J
NEURO-ONCOLOGY. 2023 [Epub ahead of print].

Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study
Erker C, Mynarek M, Bailey S, Mazewski C, Baroni L, Massimino M, Hukin J, Aguilera D, Cappellano A, Ramaswamy V, Lassaletta A, Perreault S, Kline C, Rajagopal R, Michaiel G, Zapotocky M, Santa-Maria Lopez V, La Madrid A, Cacciotti C, Sandler E, Hoffman L, Klawinski D, Khan S, Salloum R, Hoppmann A, Larouche V, Dorris K, Toledano H, Gilheeney S, Abdelbaki M, Wilson B, Tsang D, Knipstein J, Oren M, Shah S, Murray J, Ginn K, Wang Z, Fleischhack G, Obrecht D, Tonn S, Harrod V, Matheson K, Crooks B, Strother D, Cohen K, Hansford J, Mueller S, Margol A, Gajjar A, Dhall G, Finlay J, Northcott P, Rutkowski S, Clifford S, Robinson G, Bouffet E, Lafay-Cousin L
J CLIN ONCOL. 2023;41(10):1921-1932.

Mitochondrial DNA mutations in Medulloblastoma
Funke V, Sandmann S, Melcher V, Seggewiss J, Horvath J, Jäger N, Kool M, Jones D, Pfister S, Milde T, Rutkowski S, Mynarek M, Varghese J, Sträter R, Rust S, Seelhöfer A, Reunert J, Fiedler B, Schüller U, Marquardt T, Kerl K
ACTA NEUROPATHOL COM. 2023;11(1):124.

Group-specific cellular metabolism in Medulloblastoma
Funke V, Walter C, Melcher V, Wei L, Sandmann S, Hotfilder M, Varghese J, Jäger N, Kool M, Jones D, Pfister S, Milde T, Mynarek M, Rutkowski S, Seggewiss J, Jeising D, de Faria F, Marquardt T, Albert T, Schüller U, Kerl K
J TRANSL MED. 2023;21(1):363.

Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification
Goddard J, Castle J, Southworth E, Fletcher A, Crosier S, Martin-Guerrero I, García-Ariza M, Navajas A, Masliah-Planchon J, Bourdeaut F, Dufour C, Ayrault O, Goschzik T, Pietsch T, Sill M, Pfister S, Rutkowski S, Richardson S, Hill R, Williamson D, Bailey S, Schwalbe E, Clifford S, Hicks D
ACTA NEUROPATHOL. 2023;145(5):651-666.

Correction: Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT
Hauch R, Hinrichs M, Ruhwald R, Schrum J, Rutkowski S, Woessmann W, Winkler B
KLIN PADIATR. 2023;235(3):e1-e2.

Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT: A Monocentric, Retrospective Study
Hauch R, Hinrichs M, Ruhwald R, Schrum J, Rutkowski S, Woessmann W, Winkler B
KLIN PADIATR. 2023;235(3):159-166.

Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome
Kolodziejczak A, Guerrini-Rousseau L, Planchon J, Ecker J, Selt F, Mynarek M, Obrecht D, Sill M, Autry R, Zhao E, Hirsch S, Amouyal E, Dufour C, Ayrault O, Torrejon J, Waszak S, Ramaswamy V, Pentikainen V, Demir H, Clifford S, Schwalbe E, Massimi L, Snuderl M, Galbraith K, Karajannis M, Hill K, Li B, Walsh M, White C, Redmond S, Loizos L, Jakob M, Kordes U, Schmid I, Hauer J, Blattmann C, Filippidou M, Piccolo G, Scheurlen W, Farrag A, Grund K, Sutter C, Pietsch T, Frank S, Schewe D, Malkin D, Ben-Arush M, Sehested A, Wong T, Wu K, Liu Y, Carceller F, Mueller S, Stoller S, Taylor M, Tabori U, Bouffet E, Kool M, Sahm F, von Deimling A, Korshunov A, von Hoff K, Kratz C, Sturm D, Jones D, Rutkowski S, van Tilburg C, Witt O, Bougeard G, Pajtler K, Pfister S, Bourdeaut F, Milde T
NEURO-ONCOLOGY. 2023;25(12):2273-2286.

Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects
Kresbach C, Holst L, Schoof M, Leven T, Göbel C, Neyazi S, Tischendorf J, Loose C, Wrzeszcz A, Yorgan T, Rutkowski S, Schüller U
NEURO-ONCOLOGY. 2023 [Epub ahead of print].

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
Mynarek M, Obrecht D, Sill M, Sturm D, Kloth-Stachnau K, Selt F, Ecker J, von Hoff K, Juhnke B, Goschzik T, Pietsch T, Bockmayr M, Kool M, von Deimling A, Witt O, Schüller U, Benesch M, Gerber N, Sahm F, Jones D, Korshunov A, Pfister S, Rutkowski S, Milde T
ACTA NEUROPATHOL. 2023;145(1):97-112.

A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymoma
Ng C, Obrecht D, Wells O, Zapotocky M, Sumerauer D, Coltin H, Khuong-Quang D, Eisenstat D, Kinross K, White C, Algar E, Luck A, Witt H, Schüller U, Mynarek M, Pietsch T, Gerber N, Benesch M, Warmuth-Metz M, Kortmann R, Bison B, Taylor M, Rutkowski S, Pfister S, Jones D, Gottardo N, von Hoff K, Pajtler K, Ramaswamy V, Hansford J
NEURO-ONCOL ADV. 2023;5(1):vdad057.

Kinder und Jugendliche mit intrakraniellem Ependymom – Empfehlungen der HIT-MED-Studiengruppe der GPOH zur Erstlinientherapie
Obrecht D, Mynarek M, Stickan-Verfürth M, Bison B, Schüller U, Pajtler K, Hagel C, Thomale U, Fleischhack G, Timmermann B, Rutkowski S
KLIN PADIATR. 2023;235(3):167-177.

Emotional and behavioral problems of pediatric cancer survivors and their siblings: Concordance of child self-report and parent proxy-report
Paul V, Inhestern L, Winzig J, Nasse M, Krauth K, Rutkowski S, Escherich G, Bergelt C
PSYCHO-ONCOLOGY. 2023;32(8):1248-1256.

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures
Schoof M, Godbole S, Albert T, Dottermusch M, Walter C, Ballast A, Qin N, Olivera M, Göbel C, Neyazi S, Holdhof D, Kresbach C, Peter L, Epplen G, Thaden V, Spohn M, Blattner-Johnson M, Modemann F, Mynarek M, Rutkowski S, Sill M, Varghese J, Afflerbach A, Eckhardt A, Münter D, Verma A, Struve N, Jones D, Remke M, Neumann J, Kerl K, Schüller U
NAT COMMUN. 2023;14(1):7717.

Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology
Sturm D, Capper D, Andreiuolo F, Gessi M, Kölsche C, Reinhardt A, Sievers P, Wefers A, Ebrahimi A, Suwala A, Gielen G, Sill M, Schrimpf D, Stichel D, Hovestadt V, Daenekas B, Rode A, Hamelmann S, Previti C, Jäger N, Buchhalter I, Blattner-Johnson M, Jones B, Warmuth-Metz M, Bison B, Grund K, Sutter C, Hirsch S, Dikow N, Hasselblatt M, Schüller U, Gerber N, White C, Buntine M, Kinross K, Algar E, Hansford J, Gottardo N, Hernáiz Driever P, Gnekow A, Witt O, Müller H, Calaminus G, Fleischhack G, Kordes U, Mynarek M, Rutkowski S, Frühwald M, Kramm C, von Deimling A, Pietsch T, Sahm F, Pfister S, Jones D
NAT MED. 2023;29(4):917-926.

Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy
Tonn S, Korshunov A, Obrecht D, Sill M, Spohn M, von Hoff K, Milde T, Pietsch T, Goschzik T, Bison B, Juhnke B, Struve N, Sturm D, Sahm F, Bockmayr M, Friedrich C, von Bueren A, Gerber N, Benesch M, Jones D, Kool M, Wefers A, Schüller U, Pfister S, Rutkowski S, Mynarek M
NEURO-ONCOLOGY. 2023;25(8):1518-1529.

Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level
Voß H, Godbole S, Schlumbohm S, Schumann Y, Peng B, Mynarek M, Rutkowski S, Dottermusch M, Dorostkar M, Koshunov A, Mair T, Pfister S, Neumann P, Hartmann C, Weis J, Liesche-Starnecker F, Guan Y, Schlüter H, Schüller U, Krisp C, Neumann J
bioRxiv. 2023;2023:.

Parent-reported health-related quality of life in pediatric childhood cancer survivors and factors associated with poor health-related quality of life in aftercare
Winzig J, Inhestern L, Paul V, Nasse M, Krauth K, Kandels D, Rutkowski S, Escherich G, Bergelt C
QUAL LIFE RES. 2023;32(10):2965-2974.

2022

Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial
Bailey S, André N, Gandola L, Massimino M, Rutkowski S, Clifford S
CANCERS. 2022;14(2):.

Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease
Bockmayr M, Harnisch K, Pohl L, Schweizer L, Mohme T, Körner M, Alawi M, Suwala A, Dorostkar M, Monoranu C, Hasselblatt M, Wefers A, Capper D, Hench J, Frank S, Richardson T, Tran I, Liu E, Snuderl M, Engertsberger L, Benesch M, von Deimling A, Obrecht D, Mynarek M, Rutkowski S, Glatzel M, Neumann J, Schüller U
NEURO-ONCOLOGY. 2022;24(10):1689-1699.

Looking back: Identifying supportive care and unmet needs of parents of children receiving specialist paediatric palliative care from the bereavement perspective
Bronsema A, Theißen T, Oechsle K, Wikert J, Escherich G, Rutkowski S, Bokemeyer C, Ullrich A
BMC PALLIAT CARE. 2022;21(1):.

Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients
Diaz Coronado R, Mynarek M, Koelsche C, Mora Alferez P, Casavilca Zambrano S, Wachtel Aptowitzer A, Sahm F, von Deimling A, Schüller U, Spohn M, Sturm D, Pfister S, Morales La Madrid A, Sernaque Quintana R, Sarria Bardales G, Negreiros Chinchihuara T, Ojeda Medina L, Garcia-Corrochano Medina P, Campos Sanchez D, Ponce Farfan J, Rutkowski S, Garcia Leon J
CANCER-AM CANCER SOC. 2022;128(4):697-707.

Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial
Dietzsch S, Braesigk A, Seidel C, Remmele J, Kitzing R, Schlender T, Mynarek M, Geismar D, Jablonska K, Schwarz R, Pazos M, Weber D, Frick S, Gurtner K, Matuschek C, Harrabi S, Glück A, Lewitzki V, Dieckmann K, Benesch M, Gerber N, Obrecht D, Rutkowski S, Timmermann B, Kortmann R
STRAHLENTHER ONKOL. 2022;198(3):282-290.

Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study
Gaab C, Adolph J, Tippelt S, Mikasch R, Obrecht D, Mynarek M, Rutkowski S, Pfister S, Milde T, Witt O, Bison B, Warmuth-Metz M, Kortmann R, Dietzsch S, Pietsch T, Timmermann B, Sträter R, Bode U, Faldum A, Kwiecien R, Fleischhack G
CANCERS. 2022;14(3):.

Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas
Goschzik T, Mynarek M, Doerner E, Schenk A, Spier I, Warmuth-Metz M, Bison B, Obrecht D, Struve N, Kortmann R, Schmid M, Aretz S, Rutkowski S, Pietsch T
ACTA NEUROPATHOL. 2022;144(6):1143-1156.

Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial
Hagel C, Sloman V, Mynarek M, Petrasch K, Obrecht D, Kühl J, Deinlein F, Schmid R, von Bueren A, Friedrich C, Juhnke B, Gerber N, Kwiecien R, Girschick H, Höller A, Zapf A, von Hoff K, Rutkowski S
EUR J CANCER. 2022;164:30-38.

ALK inhibition as a salvage therapy for a relapsed unclassifiable sarcomatous CNS tumor with EML4/ALK fusion in an infant
Holsten T, Bronsema A, Sturm D, Sahm F, Rutkowski S, Ulrich S, Wößmann W, Kordes U
PEDIATR BLOOD CANCER. 2022;69(8):.

Children with cancer and their families after active treatment: analyses of biopsychosocial needs and implications for healthcare - a study protocol
Inhestern L, Paul V, Winzig J, Rutkowski S, Escherich G, Bergelt C
BMJ OPEN. 2022;12(4):e055633.

Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial
Juhnke B, Gessi M, Gerber N, Friedrich C, Mynarek M, von Bueren A, Haberler C, Schüller U, Kortmann R, Timmermann B, Bison B, Warmuth-Metz M, Kwiecien R, Pfister S, Spix C, Pietsch T, Kool M, Rutkowski S, von Hoff K
NEURO-ONCOLOGY. 2022;24(1):127-137.

Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling
Kresbach C, Bronsema A, Guerreiro H, Rutkowski S, Schüller U, Winkler B
CHILD NERV SYST. 2022;38(2):479-483.

MODL-03. Establishment of intraventricular Shh inhibition as a therapeutic option for young patients with medulloblastoma
Kresbach C, Schoof M, Holst L, Leven T, Yorgan T, Wrzeszcz A, Rutkowski S, Schüller U
NEURO-ONCOLOGY. 2022;24(S1):i168.

Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies
Obrecht D, Mynarek M, Hagel C, Kwiecien R, Spohn M, Bockmayr M, Bison B, Pfister S, Jones D, Sturm D, von Deimling A, Sahm F, von Hoff K, Juhnke B, Benesch M, Gerber N, Friedrich C, von Bueren A, Kortmann R, Schwarz R, Pietsch T, Fleischhack G, Schüller U, Rutkowski S
J NEURO-ONCOL. 2022;157(1):37-48.

Fear of progression in parents of childhood cancer survivors: prevalence and associated factors
Peikert M, Inhestern L, Krauth K, Escherich G, Rutkowski S, Kandels D, Schiekiera L, Bergelt C
J CANCER SURVIV. 2022;16(4):823-833.

Proton Beam Therapy for Pediatric Tumors of the Central Nervous System-Experiences of Clinical Outcome and Feasibility from the KiProReg Study
Peters S, Frisch S, Stock A, Merta J, Bäumer C, Blase C, Schuermann E, Tippelt S, Bison B, Frühwald M, Rutkowski S, Fleischhack G, Timmermann B
CANCERS. 2022;14(23):.

Evaluation of dose, volume and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study
Peters S, Merta J, Schmidt L, Jazmati D, Kramer P, Blase C, Tippelt S, Fleischhack G, Stock A, Bison B, Rutkowski S, Pietsch T, Kortmann R, Timmermann B
NEURO-ONCOLOGY. 2022;24(7):1193-1202.

2021

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies
Adolph J, Fleischhack G, Gaab C, Mikasch R, Mynarek M, Rutkowski S, Schüller U, Pfister S, Pajtler K, Milde T, Witt O, Bison B, Warmuth-Metz M, Kortmann R, Dietzsch S, Pietsch T, Timmermann B, Tippelt S
J NEURO-ONCOL. 2021;155(2):193-202.

Local and Systemic Therapy of Recurrent Ependymoma in Children and Adolescents: Short- and Long-term Results of the E-HIT-REZ 2005 Study
Adolph J, Fleischhack G, Mikasch R, Zeller J, Warmuth-Metz M, Bison B, Mynarek M, Rutkowski S, Schüller U, von Hoff K, Obrecht D, Pietsch T, Pfister S, Pajtler K, Witt O, Witt H, Kortmann R, Timmermann B, Krauß J, Frühwald M, Faldum A, Kwiecien R, Bode U, Tippelt S
NEURO-ONCOLOGY. 2021;23(6):1012-1023.

Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma: First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial
Dietzsch S, Braesigk A, Seidel C, Remmele J, Kitzing R, Schlender T, Mynarek M, Geismar D, Jablonska K, Schwarz R, Pazos M, Walser M, Frick S, Gurtner K, Matuschek C, Harrabi S, Glück A, Lewitzki V, Dieckmann K, Benesch M, Gerber N, Rutkowski S, Timmermann B, Kortmann R
STRAHLENTHER ONKOL. 2021;197(8):674-682.

Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment
Hill R, Plasschaert S, Timmermann B, Dufour C, Aquilina K, Avula S, Donovan L, Lequin M, Pietsch T, Thomale U, Tippelt S, Wesseling P, Rutkowski S, Clifford S, Pfister S, Bailey S, Fleischhack G
CANCERS. 2021;14(1):.

Detailed Clinical and Histopathological Description of 8 Cases of Molecularly Defined CNS Neuroblastomas
Holsten T, Lubieniecki F, Spohn M, Mynarek M, Bison B, Löbel U, Rutkowski S, Schüller U
J NEUROPATH EXP NEUR. 2021;80(1):52-59.

Feasibility of Proton Beam Therapy for Infants with Brain Tumours: Experiences from the Prospective KiProReg Registry Study
Jazmati D, Steinmeier T, Ahamd Khalil D, Frisch S, Peters S, Schulze Schleithoff S, Bäumer C, Rutkowski S, Frühwald M, Blase C, Tippelt S, Timmermann B
CLIN ONCOL-UK. 2021;33(7):e295-e304.

Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort
Kloth K, Obrecht D, Sturm D, Pietsch T, Warmuth-Metz M, Bison B, Mynarek M, Rutkowski S
FRONT ONCOL. 2021;11:.

Sarcoma classification by DNA methylation profiling
Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss D, Blattner M, Worst B, Heilig C, Beck K, Horak P, Kreutzfeldt S, Paff E, Stark S, Johann P, Selt F, Ecker J, Sturm D, Pajtler K, Reinhardt A, Wefers A, Sievers P, Ebrahimi A, Suwala A, Fernández-Klett F, Casalini B, Korshunov A, Hovestadt V, Kommoss F, Kriegsmann M, Schick M, Bewerunge-Hudler M, Milde T, Witt O, Kulozik A, Kool M, Romero-Pérez L, Grünewald T, Kirchner T, Wick W, Platten M, Unterberg A, Uhl M, Abdollahi A, Debus J, Lehner B, Thomas C, Hasselblatt M, Paulus W, Hartmann C, Staszewski O, Prinz M, Hench J, Frank S, Versleijen-Jonkers Y, Weidema M, Mentzel T, Griewank K, de Álava E, Martín J, Gastearena M, Chang K, Low S, Cuevas-Bourdier A, Mittelbronn M, Mynarek M, Rutkowski S, Schüller U, Mautner V, Schittenhelm J, Serrano J, Snuderl M, Büttner R, Klingebiel T, Buslei R, Gessler M, Wesseling P, Dinjens W, Brandner S, Jaunmuktane Z, Lyskjær I, Schirmacher P, Stenzinger A, Brors B, Glimm H, Heining C, Tirado O, Sáinz-Jaspeado M, Mora J, Alonso J, Del Muro X, Moran S, Esteller M, Benhamida J, Ladanyi M, Wardelmann E, Antonescu C, Flanagan A, Dirksen U, Hohenberger P, Baumhoer D, Hartmann W, Vokuhl C, Flucke U, Petersen I, Mechtersheimer G, Capper D, Jones D, Fröhling S, Pfister S, von Deimling A
NAT COMMUN. 2021;12(1):498.

Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype
Kresbach C, Dorostkar M, Suwala A, Wefers A, Schweizer L, Engertsberger L, Bison B, Mynarek M, Kloth-Stachnau K, Spohn M, von Deimling A, Benesch M, Hagel C, Mautner V, Rutkowski S, Schüller U
ACTA NEUROPATHOL. 2021;141(6):971-974.

EXTH-70. ESTABLISHMENT OF INTRAVENTRICULAR SHH INHIBITION AS A THERAPEUTIC OPTION IN YOUNG PATIENTS WITH MEDULLOBLASTOMA
Kresbach C, Schoof M, Leven T, Holst L, Yorgan T, Wrzeszcz A, Rutkowski S, Schüller U
NEURO-ONCOLOGY. 2021;23(Supplement_6):vi179.

Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma
Kumar R, Smith K, Deng M, Terhune C, Robinson G, Orr B, Liu A, Lin T, Billups C, Chintagumpala M, Bowers D, Hassall T, Hansford J, Khuong-Quang D, Crawford J, Bendel A, Gururangan S, Schroeder K, Bouffet E, Bartels U, Fisher M, Cohn R, Partap S, Kellie S, McCowage G, Paulino A, Rutkowski S, Fleischhack G, Dhall G, Klesse L, Leary S, Nazarian J, Kool M, Wesseling P, Ryzhova M, Zheludkova O, Golanov A, McLendon R, Packer R, Dunham C, Hukin J, Fouladi M, Faria C, Pimentel J, Walter A, Jabado N, Cho Y, Perreault S, Croul S, Zapotocky M, Hawkins C, Tabori U, Taylor M, Pfister S, Klimo P, Boop F, Ellison D, Merchant T, Onar-Thomas A, Korshunov A, Jones D, Gajjar A, Ramaswamy V, Northcott P
J CLIN ONCOL. 2021;39(7):807-821.

Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study
Liu A, Li B, Pfaff E, Gudenas B, Vasiljevic A, Orr B, Dufour C, Snuderl M, Karajannis M, Rosenblum M, Hwang E, Ng H, Hansford J, Szathmari A, Faure-Conter C, Merchant T, Levine M, Bouvier N, von Hoff K, Mynarek M, Rutkowski S, Sahm F, Kool M, Hawkins C, Onar-Thomas A, Robinson G, Gajjar A, Pfister S, Bouffet E, Northcott P, Jones D, Huang A
ACTA NEUROPATHOL. 2021;141(5):771-785.

Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report
Meijer A, van den Heuvel-Eibrink M, Brooks B, Am Zehnhoff-Dinnesen A, Knight K, Freyer D, Chang K, Hero B, Papadakis V, Frazier A, Blattmann C, Windsor R, Morland B, Bouffet E, Rutkowski S, Tytgat G, Geller J, Hunter L, Sung L, Calaminus G, Carleton B, Helleman H, Foster J, Kruger M, Cohn R, Landier W, van Grotel M, Brock P, Hoetink A, Rajput K
JAMA ONCOL. 2021;7(10):1550-1558.

SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma
Mynarek M, Milde T, Padovani L, Janssens G, Kwiecien R, Mosseri V, Clifford S, Doz F, Rutkowski S
CANCERS. 2021;13(23):.

Follow-up evaluation of a web-based pediatric brain tumor board in Latin America
Rosabal-Obando M, Osorio D, Lassaletta A, La Madrid A, Bartels U, Finlay J, Qaddoumi I, Rutkowski S, Mynarek M
PEDIATR BLOOD CANCER. 2021;68(9):e29073.

Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors
Sievers P, Henneken S, Blume C, Sill M, Schrimpf D, Stichel D, Okonechnikov K, Reuss D, Benzel J, Maaß K, Kool M, Sturm D, Zheng T, Ghasemi D, Kohlhof-Meinecke P, Cruz O, Suñol M, Lavarino C, Ruf V, Boldt H, Pagès M, Pouget C, Schweizer L, Kranendonk M, Akhtar N, Bunkowski S, Stadelmann C, Schüller U, Mueller W, Dohmen H, Acker T, Harter P, Mawrin C, Beschorner R, Brandner S, Snuderl M, Abdullaev Z, Aldape K, Gilbert M, Armstrong T, Ellison D, Capper D, Ichimura K, Reifenberger G, Grundy R, Jabado N, Krskova L, Zapotocky M, Vicha A, Varlet P, Wesseling P, Rutkowski S, Korshunov A, Wick W, Pfister S, Jones D, von Deimling A, Pajtler K, Sahm F
ACTA NEUROPATHOL. 2021;142(5):827-839.

Diagnostics and Diagnosis of Late Effects in Childhood Brain Tumour Survivors
Tallen G, Mynarek M, Tischler T, Weller M, Rutkowski S
2021. Late Treatment Effects and Cancer Survivor Care in the Young. Beck J, Bokemeyer C, Langer T (Hrsg.). 1. Aufl. Cham: Springer Nature Switzerland, 239-251.

Therapeutic implications of improved molecular diagnostics for rare CNS-embryonal tumor entities: results of an international, retrospective study
von Hoff K, Haberler C, Schmitt-Hoffner F, Schepke E, de Rojas T, Jacobs S, Zapotocky M, Sumerauer D, Perek-Polnik M, Dufour C, van Vuurden D, Slavc I, Gojo J, Pickles J, Gerber N, Massimino M, Gil-da-Costa M, Garami M, Kumirova E, Sehested A, Scheie D, Cruz O, Moreno L, Cho J, Zeller B, Bovenschen N, Grotzer M, Alderete D, Snuderl M, Zheludkova O, Golanov A, Okonechnikov K, Mynarek M, Juhnke B, Rutkowski S, Schüller U, Pizer B, Zezschwitz B, Kwiecien R, Wechsung M, Konietschke F, Hwang E, Sturm D, Pfister S, von Deimling A, Rushing E, Ryzhova M, Hauser P, Łastowska M, Wesseling P, Giangaspero F, Hawkins C, Figarella-Branger D, Eberhart C, Burger P, Gessi M, Korshunov A, Jacques T, Capper D, Pietsch T, Kool M
NEURO-ONCOLOGY. 2021;23(9):1597-1611.

Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas
Zheng T, Ghasemi D, Okonechnikov K, Korshunov A, Sill M, Maass K, Benites Goncalves da Silva P, Ryzhova M, Gojo J, Stichel D, Arabzade A, Kupp R, Benzel J, Taya S, Adachi T, Shiraishi R, Gerber N, Sturm D, Ecker J, Sievers P, Selt F, Chapman R, Haberler C, Figarella-Branger D, Reifenberger G, Fleischhack G, Rutkowski S, Donson A, Ramaswamy V, Capper D, Ellison D, Herold-Mende C, Schüller U, Brandner S, Driever P, Kros J, Snuderl M, Milde T, Grundy R, Hoshino M, Mack S, Gilbertson R, Jones D, Kool M, von Deimling A, Pfister S, Sahm F, Kawauchi D, Pajtler K
CANCER DISCOV. 2021;11(9):2230-2247.

Supratentorial ependymoma in childhood: more than just RELA or YAP
Zschernack V, Jünger S, Mynarek M, Rutkowski S, Garre M, Ebinger M, Neu M, Faber J, Erdlenbruch B, Claviez A, Bielack S, Brozou T, Frühwald M, Dörner E, Dreschmann V, Stock A, Solymosi L, Hench J, Frank S, Vokuhl C, Waha A, Andreiuolo F, Pietsch T
ACTA NEUROPATHOL. 2021;141(3):455-466.

2020

Treatment response of CNS high-grade neuroepithelial tumors with MN1 alteration
Baroni L, Rugilo C, Lubieniecki F, Sampor C, Freytes C, Nobre L, Hansford J, Malalasekera V, Zapotocky M, Dodgshun A, Martinez O, La Madrid A, Lavarino C, Suñol M, Rutkowski S, Schuller U, Bouffet E, Ramaswamy V, Alderete D
PEDIATR BLOOD CANCER. 2020;67(12):e28627.

Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma
Begemann M, Waszak S, Robinson G, Jäger N, Sharma T, Knopp C, Kraft F, Moser O, Mynarek M, Guerrini-Rousseau L, Brugieres L, Varlet P, Pietsch T, Bowers D, Chintagumpala M, Sahm F, Korbel J, Rutkowski S, Eggermann T, Gajjar A, Northcott P, Elbracht M, Pfister S, Kontny U, Kurth I
J CLIN ONCOL. 2020;38(1):43-50.

Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma - A Report From the HIT 2000 Trial
Dietzsch S, Placzek F, Pietschmann K, von Bueren A, Matuschek C, Glück A, Guckenberger M, Budach V, Welzel J, Pöttgen C, Schmidberger H, Heinzelmann F, Paulsen F, Escudero M, Schwarz R, Hornung D, Martini C, Grosu A, Stueben G, Jablonska K, Dunst J, Stranzl-Lawatsch H, Dieckmann K, Timmermann B, Pietsch T, Warmuth-Metz M, Bison B, Kwiecien R, Benesch M, Gerber N, Grotzer M, Pfister S, Clifford S, von Hoff K, Klagges S, Rutkowski S, Kortmann R, Mynarek M
ADV RADIAT ONCOL. 2020;5(6):1158-1169.

Age and DNA-methylation subgroup as potential independent risk factors for treatment stratification in children with Atypical Teratoid/Rhabdoid Tumors (ATRT)
Frühwald M, Hasselblatt M, Nemes K, Bens S, Steinbügl M, Johann P, Kerl K, Hauser P, Quiroga E, Solano-Paez P, Biassoni V, Gil-da-Costa M, Perek-Polnik M, van de Wetering M, Sumerauer D, Pears J, Stabell N, Holm S, Hengartner H, Gerber N, Grotzer M, Boos J, Ebinger M, Tippelt S, Paulus W, Furtwängler R, Hernáiz-Driever P, Reinhard H, Rutkowski S, Schlegel P, Schmid I, Kortmann R, Timmermann B, Warmuth-Metz M, Kordes U, Gerss J, Nysom K, Schneppenheim R, Siebert R, Kool M, Graf N
NEURO-ONCOLOGY. 2020;22(7):1006–1017.

Parents' perception of their children's process of reintegration after childhood cancer treatment
Inhestern L, Peikert M, Krauth K, Escherich G, Rutkowski S, Kandels D, Bergelt C
PLOS ONE. 2020;15(10):e0239967.

Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome
Jünger S, Andreiuolo F, Mynarek M, Dörner E, Zur Mühlen A, Rutkowski S, von Bueren A, Pietsch T
CHILD NERV SYST. 2020;36(11):2693-2700.

CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort
Jünger S, Andreiuolo F, Mynarek M, Wohlers I, Rahmann S, Klein-Hitpass L, Dörner E, Zur Mühlen A, Velez-Char N, von Hoff K, Warmuth-Metz M, Kortmann R, Timmermann B, von Bueren A, Rutkowski S, Pietsch T
ACTA NEUROPATHOL. 2020;140(3):405-407.

Young children with medulloblastoma: Important open questions and the high-risk dilemma
Mynarek M, Rutkowski S
NEURO-ONCOLOGY. 2020;22(12):1723-1724.

Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort
Mynarek M, von Hoff K, Pietsch T, Ottensmeier H, Warmuth-Metz M, Bison B, Pfister S, Korshunov A, Sharma T, Jaeger N, Ryzhova M, Zheludkova O, Golanov A, Rushing E, Hasselblatt M, Koch A, Schüller U, von Deimling A, Sahm F, Sill M, Riemenschneider M, Dohmen H, Monoranu C, Sommer C, Staszewski O, Mawrin C, Schittenhelm J, Brück W, Filipski K, Hartmann C, Meinhardt M, Pietschmann K, Haberler C, Slavc I, Gerber N, Grotzer M, Benesch M, Schlegel P, Deinlein F, von Bueren A, Friedrich C, Juhnke B, Obrecht D, Fleischhack G, Kwiecien R, Faldum A, Kortmann R, Kool M, Rutkowski S
J CLIN ONCOL. 2020;38(18):2028-2040.

Molecular characterization of histopathological ependymoma variants
Neumann J, Spohn M, Obrecht D, Mynarek M, Thomas C, Hasselblatt M, Dorostkar M, Wefers A, Frank S, Monoranu C, Koch A, Witt H, Kool M, Pajtler K, Rutkowski S, Glatzel M, Schüller U
ACTA NEUROPATHOL. 2020;139(2):305-318.

Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
Ottensmeier H, Schlegel P, Eyrich M, Wolff J, Juhnke B, von Hoff K, Frahsek S, Schmidt R, Faldum A, Fleischhack G, von Bueren A, Friedrich C, Resch A, Warmuth-Metz M, Krauss J, Kortmann R, Bode U, Kühl J, Rutkowski S
PLOS ONE. 2020;15(1):e0227693.

Fear of progression in parents of childhood cancer survivors: A Dyadic data analysis
Peikert M, Inhestern L, Krauth K, Escherich G, Rutkowski S, Kandels D, Bergelt C
PSYCHO-ONCOLOGY. 2020;29(10):1678-1685.

Returning to daily life: a qualitative interview study on parents of childhood cancer survivors in Germany
Peikert M, Inhestern L, Krauth K, Escherich G, Rutkowski S, Kandels D, Bergelt C
BMJ OPEN. 2020;10(3):e033730.

Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations
Pfaff E, Aichmüller C, Sill M, Stichel D, Snuderl M, Karajannis M, Schuhmann M, Schittenhelm J, Hasselblatt M, Thomas C, Korshunov A, Rhizova M, Wittmann A, Kaufhold A, Iskar M, Ketteler P, Lohmann D, Orr B, Ellison D, von Hoff K, Mynarek M, Rutkowski S, Sahm F, von Deimling A, Lichter P, Kool M, Zapatka M, Pfister S, Jones D
ACTA NEUROPATHOL. 2020;139(2):243-257.

Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review
Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub L, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D, Dirksen U, Sander A, Köhler M, Habermann J, Bokemeyer C, Stein A
BMC CANCER. 2020;20(1):16.

Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS)
Scheer M, Blank B, Bauer S, Vokuhl C, Stegmaier S, Feuchtgruber S, Henssen A, Sparber-Sauer M, Eggert A, Handgretinger R, Pekrun A, Rossig C, Rutkowski S, Schlegel P, Schrappe M, Simon T, Kazanowska B, Niggli F, Ladenstein R, Ljungman G, Jahnukainen K, Fuchs J, Bielack S, Koscielniak E, Klingebiel T
J CANCER RES CLIN. 2020;146(4):953-960.

Effects of the growth pattern of medulloblastoma on short-term neurological impairments after surgery: results from the prospective multicenter HIT-SIOP PNET 4 study
Schepke E, Tisell M, Kennedy C, Puget S, Ferroli P, Chevignard M, Doz F, Pizer B, Rutkowski S, Massimino M, Navajas A, Schwalbe E, Hicks D, Clifford S, Pietsch T, Lannering B
J NEUROSURG-PEDIATR. 2020;1-9.

Cerebrospinal fluid evaluation in adult patients with medulloblastoma
von Bueren A, Hagel C, Rutkowski S
LANCET ONCOL. 2020;21(3):e120.

Germline Elongator mutations in Sonic Hedgehog medulloblastoma
Waszak S, Robinson G, Gudenas B, Smith K, Forget A, Kojic M, Garcia-Lopez J, Hadley J, Hamilton K, Indersie E, Buchhalter I, Kerssemakers J, Jäger N, Sharma T, Rausch T, Kool M, Sturm D, Jones D, Vasilyeva A, Tatevossian R, Neale G, Lombard B, Loew D, Nakitandwe J, Rusch M, Bowers D, Bendel A, Partap S, Chintagumpala M, Crawford J, Gottardo N, Smith A, Dufour C, Rutkowski S, Eggen T, Wesenberg F, Kjaerheim K, Feychting M, Lannering B, Schüz J, Johansen C, Andersen T, Röösli M, Kuehni C, Grotzer M, Remke M, Puget S, Pajtler K, Milde T, Witt O, Ryzhova M, Korshunov A, Orr B, Ellison D, Brugieres L, Lichter P, Nichols K, Gajjar A, Wainwright B, Ayrault O, Korbel J, Northcott P, Pfister S
NATURE. 2020;580(7803):396-401.

2019

Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series
Benesch M, Mynarek M, Witt H, Warmuth-Metz M, Pietsch T, Bison B, Pfister S, Pajtler K, Kool M, Schüller U, Pietschmann K, Juhnke B, Tippelt S, Fleischhack G, Schmid I, Kramm C, Vorwerk P, Beilken A, Classen C, Hernáiz Driever P, Kropshofer G, Imschweiler T, Lemmer A, Kortmann R, Rutkowski S, von Hoff K
ONCOLOGIST. 2019;24(9):e921-e929.

Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas
Bockmayr M, Klauschen F, Maire C, Rutkowski S, Westphal M, Lamszus K, Schüller U, Mohme M
CANCER IMMUNOL RES. 2019;7(9):1401-1411.

Clostridium difficile infection after pediatric solid organ transplantation: a practical single-center experience
Breuer C, Döring S, Rohde H, Rutkowski S, Müller I, Oh J
PEDIATR NEPHROL. 2019;34(7):1269-1275.

Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study
Fleischhack G, Massimino M, Warmuth-Metz M, Khuhlaeva E, Janssen G, Graf N, Rutkowski S, Beilken A, Schmid I, Biassoni V, Gorelishev S, Kramm C, Reinhard H, Schlegel P, Kortmann R, Reuter D, Bach F, Iznaga-Escobar N, Bode U
J NEURO-ONCOL. 2019;143(1):107-113.

Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort
Jünger S, Mynarek M, Wohlers I, Dörner E, Mühlen A, Velez-Char N, von Hoff K, Rutkowski S, Warmuth-Metz M, Kortmann R, Timmermann B, Rahmann S, Klein-Hitpass L, von Bueren A, Pietsch T
ACTA NEUROPATHOL COM. 2019;7(1):181.

Medulloblastoma
Northcott P, Robinson G, Kratz C, Mabbott D, Pomeroy S, Clifford S, Rutkowski S, Ellison D, Malkin D, Taylor M, Gajjar A, Pfister S
NAT REV DIS PRIMERS. 2019;5(1):11.

MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma
Nowak J, Jünger S, Huflage H, Seidel C, Hohm A, Vandergrift L, von Hoff K, Rutkowski S, Pietsch T, Warmuth-Metz M
CLIN NEURORADIOL. 2019;29(4):595-604.

Relapse of a group 4 medulloblastoma after 18 years as proven by histology and DNA methylation profiling
Ricklefs F, Fritzsche F, Winkler B, Meissner B, Dührsen L, Westphal M, Rutkowski S, Martens T, Schüller U
CHILD NERV SYST. 2019;35(6):1029-1033.

Health status, Health-Related Quality of Life and Socio-economic Outcome in Childhood Brain Tumor Survivors: a German Cohort Study
Scholtes C, Baust K, Weinhold L, Creutzig U, Gnekow A, Hinz A, Kaatsch P, Kreitz K, Langer T, Rutkowski S, Singer S, Spix C, Teske C, Schmid M, Dilloo D, Calaminus G
NEURO-ONCOLOGY. 2019 [Epub ahead of print];2019(21):1069-1081.

Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
Sharma T, Schwalbe E, Williamson D, Sill M, Hovestadt V, Mynarek M, Rutkowski S, Robinson G, Gajjar A, Cavalli F, Ramaswamy V, Taylor M, Lindsey J, Hill R, Jäger N, Korshunov A, Hicks D, Bailey S, Kool M, Chavez L, Northcott P, Pfister S, Clifford S
ACTA NEUROPATHOL. 2019;138(2):309-326.

Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort
Stock A, Mynarek M, Pietsch T, Pfister S, Clifford S, Goschzik T, Sturm D, Schwalbe E, Hicks D, Rutkowski S, Bison B, Pham M, Warmuth-Metz M
AM J NEURORADIOL. 2019;40(11):1811-1817.

2018

Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)
Beier D, Proescholdt M, Reinert C, Pietsch T, Jones D, Pfister S, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann R, Bogdahn U, Hau P
NEURO-ONCOLOGY. 2018;20(3):400-410.

Subgroup-specific immune and stromal microenvironment in medulloblastoma
Bockmayr M, Mohme M, Klauschen F, Winkler B, Budczies J, Rutkowski S, Schüller U
ONCOIMMUNOLOGY. 2018;7(9):e1462430.

DNA methylation-based classification of central nervous system tumours
Capper D, Jones D, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss D, Kratz A, Wefers A, Huang K, Pajtler K, Schweizer L, Stichel D, Olar A, Engel N, Lindenberg K, Harter P, Braczynski A, Plate K, Dohmen H, Garvalov B, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez F, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford J, Kohlhof P, Kristensen B, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo N, Driever P, Kramm C, Müller H, Rutkowski S, von Hoff K, Frühwald M, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu C, Perry A, Jones C, Jacques T, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins V, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott P, Paulus W, Gajjar A, Robinson G, Taylor M, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis M, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison D, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister S
NATURE. 2018;555(7697):469-474.

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
Goschzik T, Schwalbe E, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford S
LANCET ONCOL. 2018;19(12):1602-1616.

Author Correction: The landscape of genomic alterations across childhood cancers
Gröbner S, Worst B, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva V, Johann P, Balasubramanian G, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik A, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter G, Schulte J, Siebert R, Westermann F, Molenaar J, Vassal G, Witt H, Burkhardt B, Kratz C, Witt O, van Tilburg C, Kramm C, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick A, Zhang J, Liu Y, Zhou X, Waanders A, Zwijnenburg D, Raman P, Brors B, Weber U, Northcott P, Pajtler K, Kool M, Piro R, Korbel J, Schlesner M, Eils R, Jones D, Lichter P, Chavez L, Zapatka M, Pfister S
NATURE. 2018;559(7714):E10.

The landscape of genomic alterations across childhood cancers
Gröbner S, Worst B, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva V, Johann P, Balasubramanian G, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik A, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter G, Schulte J, Siebert R, Westermann F, Molenaar J, Vassal G, Witt H, Burkhardt B, Kratz C, Witt O, van Tilburg C, Kramm C, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick A, Zhang J, Liu Y, Zhou X, Waanders A, Zwijnenburg D, Raman P, Brors B, Weber U, Northcott P, Pajtler K, Kool M, Piro R, Korbel J, Schlesner M, Eils R, Jones D, Lichter P, Chavez L, Zapatka M, Pfister S
NATURE. 2018;555(7696):321-327.

Group 3 medulloblastoma in a patient with a GYS2 germline mutation and glycogen storage disease 0a
Holsten T, Tsiakas K, Kordes U, Bison B, Pietsch T, Rutkowski S, Santer R, Schüller U
CHILD NERV SYST. 2018;34(3):581-584.

Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations
Koelsche C, Mynarek M, Schrimpf D, Bertero L, Serrano J, Sahm F, Reuss D, Hou Y, Baumhoer D, Vokuhl C, Flucke U, Petersen I, Brück W, Rutkowski S, Zambrano S, Garcia Leon J, Diaz Coronado R, Gessler M, Tirado O, Mora J, Alonso J, Garcia Del Muro X, Esteller M, Sturm D, Ecker J, Milde T, Pfister S, Korshunov A, Snuderl M, Mechtersheimer G, Schüller U, Jones D, von Deimling A
ACTA NEUROPATHOL. 2018;136(2):327-337.

Hirntumoren des Kindes- und Jugendalters
Rutkowski S
TUMORDIAGN THER. 2018;39(08):513-517.

Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group
Rutkowski S, Modena P, Williamson D, Kerl K, Nysom K, Pizer B, Bartels U, Puget S, Doz F, Michalski A, von Hoff K, Chevignard M, Avula S, Murray M, Schönberger S, Czech T, Schouten-van Meeteren A, Kordes U, Kramm C, van Vuurden D, Hulleman E, Janssens G, Solanki G, van Veelen M, Thomale U, Schuhmann M, Jones C, Giangaspero F, Figarella-Branger D, Pietsch T, Clifford S, Pfister S, Van Gool S
LANCET ONCOL. 2018;19(8):e419-e428.

Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
Waszak S, Northcott P, Buchhalter I, Robinson G, Sutter C, Groebner S, Grund K, Brugières L, Jones D, Pajtler K, Morrissy A, Kool M, Sturm D, Chavez L, Ernst A, Brabetz S, Hain M, Zichner T, Segura-Wang M, Weischenfeldt J, Rausch T, Mardin B, Zhou X, Baciu C, Lawerenz C, Chan J, Varlet P, Guerrini-Rousseau L, Fults D, Grajkowska W, Hauser P, Jabado N, Ra Y, Zitterbart K, Shringarpure S, De La Vega F, Bustamante C, Ng H, Perry A, MacDonald T, Hernáiz Driever P, Bendel A, Bowers D, McCowage G, Chintagumpala M, Cohn R, Hassall T, Fleischhack G, Eggen T, Wesenberg F, Feychting M, Lannering B, Schüz J, Johansen C, Andersen T, Röösli M, Kuehni C, Grotzer M, Kjaerheim K, Monoranu C, Archer T, Duke E, Pomeroy S, Shelagh R, Frank S, Sumerauer D, Scheurlen W, Ryzhova M, Milde T, Kratz C, Samuel D, Zhang J, Solomon D, Marra M, Eils R, Bartram C, von Hoff K, Rutkowski S, Ramaswamy V, Gilbertson R, Korshunov A, Taylor M, Lichter P, Malkin D, Gajjar A, Korbel J, Pfister S
LANCET ONCOL. 2018;19(6):785-798.

Exploring the potential of a pretend play intervention in young patients with leukemia
Witt S, Escherich G, Rutkowski S, Kappelhoff G, Frygner-Holm S, Russ S, Bullinger M, Quitmann J
J PEDIATR NURS. 2018;44:E98-E106.

2017

Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification
Andreiuolo F, Le Teuff G, Bayar M, Kilday J, Pietsch T, von Bueren A, Witt H, Korshunov A, Modena P, Pfister S, Pagès M, Castel D, Giangaspero F, Chimelli L, Varlet P, Rutkowski S, Frappaz D, Massimino M, Grundy R, Grill J
PLOS ONE. 2017;12(6):e0178351.

Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response
Friedrich C, Shalaby T, Oehler C, Pruschy M, Seifert B, Picard D, Remke M, Warmuth-Metz M, Kortmann R, Rutkowski S, Grotzer M, von Bueren A
CHILD NERV SYST. 2017;33(9):1463-1471.

Geographical variability in survival of European children with central nervous system tumours
Gatta G, Peris-Bonet R, Visser O, Stiller C, Marcos-Gragera R, Sánchez M, Lacour B, Kaatsch P, Berrino F, Rutkowski S, Botta L
EUR J CANCER. 2017;82:137-148.

Refining medulloblastoma subgroups
Juhnke B, Mynarek M, Rutkowski S
LANCET ONCOL. 2017;18(7):847-848.

Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN
Kilday J, Caldarelli M, Massimi L, Chen R, Lee Y, Liang M, Parkes J, Naiker T, van Veelen M, Michiels E, Mallucci C, Pettorini B, Meijer L, Dorfer C, Czech T, Diezi M, Schouten-van Meeteren A, Holm S, Gustavsson B, Benesch M, Müller H, Hoffmann A, Rutkowski S, Flitsch J, Escherich G, Grotzer M, Spoudeas H, Azquikina K, Capra M, Jiménez-Guerra R, MacDonald P, Johnston D, Dvir R, Constantini S, Kuo M, Yang S, Bartels U
NEURO-ONCOLOGY. 2017;19(10):1398-1407.

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy
Louis D, Aldape K, Brat D, Capper D, Ellison D, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor T, Cairncross J, Pfister S, Rutkowski S, Weller M, Wick W, von Deimling A
ACTA NEUROPATHOL. 2017;133(1):1-3.

cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification
Louis D, Aldape K, Brat D, Capper D, Ellison D, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor T, Gregory Cairncross J, Pfister S, Rutkowski S, Weller M, Wick W, von Deimling A
BRAIN PATHOL. 2017;27(6):851-852.

Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data
Mynarek M, Pizer B, Dufour C, van Vuurden D, Garami M, Massimino M, Fangusaro J, Davidson T, Gil-da-Costa M, Sterba J, Benesch M, Gerber N, Juhnke B, Kwiecien R, Pietsch T, Kool M, Clifford S, Ellison D, Giangaspero F, Wesseling P, Gilles F, Gottardo N, Finlay J, Rutkowski S, von Hoff K
NEURO-ONCOLOGY. 2017;19(4):576-585.

Das CARE-for-CAYA-Programm. Präventionskonzept für junge Menschen nach Krebserkrankung
Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2017;32(06):479-484.

Versorgung von Patienten nach Krebserkrankung im Kindes-, Jugend- oder jungen Erwachsenenalter
Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
J Onkol - Z Onkol Fortb. 2017;2017(10):862-866.

Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology
Ripperger T, Bielack S, Borkhardt A, Brecht I, Burkhardt B, Calaminus G, Debatin K, Deubzer H, Dirksen U, Eckert C, Eggert A, Erlacher M, Fleischhack G, Frühwald M, Gnekow A, Goehring G, Graf N, Hanenberg H, Hauer J, Hero B, Hettmer S, von Hoff K, Horstmann M, Hoyer J, Illig T, Kaatsch P, Kappler R, Kerl K, Klingebiel T, Kontny U, Kordes U, Körholz D, Koscielniak E, Kramm C, Kuhlen M, Kulozik A, Lamottke B, Leuschner I, Lohmann D, Meinhardt A, Metzler M, Meyer L, Moser O, Nathrath M, Niemeyer C, Nustede R, Pajtler K, Paret C, Rasche M, Reinhardt D, Rieß O, Russo A, Rutkowski S, Schlegelberger B, Schneider D, Schneppenheim R, Schrappe M, Schroeder C, von Schweinitz D, Simon T, Sparber-Sauer M, Spix C, Stanulla M, Steinemann D, Strahm B, Temming P, Thomay K, von Bueren A, Vorwerk P, Witt O, Wlodarski M, Wössmann W, Zenker M, Zimmermann S, Pfister S, Kratz C
AM J MED GENET A. 2017;173(4):1017-1037.

Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures
Schwalbe E, Hicks D, Rafiee G, Bashton M, Gohlke H, Enshaei A, Potluri S, Matthiesen J, Mather M, Taleongpong P, Chaston R, Silmon A, Curtis A, Lindsey J, Crosier S, Smith A, Goschzik T, Doz F, Rutkowski S, Lannering B, Pietsch T, Bailey S, Williamson D, Clifford S
SCI REP-UK. 2017;7(1):13421.

2016

MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties
Dietl S, Schwinn S, Dietl S, Riedel S, Deinlein F, Rutkowski S, von Bueren A, Krauss J, Schweitzer T, Vince G, Picard D, Eyrich M, Rosenwald A, Ramaswamy V, Taylor M, Remke M, Monoranu C, Beilhack A, Schlegel P, Wölfl M
BMC CANCER. 2016;16(1):115.

Evidence of H3 K27M mutations in posterior fossa ependymomas
Gessi M, Capper D, Sahm F, Huang K, von Deimling A, Tippelt S, Fleischhack G, Scherbaum D, Alfer J, Juhnke B, von Hoff K, Rutkowski S, Warmuth-Metz M, Chavez L, Pfister S, Pietsch T, Jones D, Sturm D
ACTA NEUROPATHOL. 2016;132(4):635-7.

Childhood medulloblastoma
Massimino M, Biassoni V, Gandola L, Garrè M, Gatta G, Giangaspero F, Poggi G, Rutkowski S
CRIT REV ONCOL HEMAT. 2016;105:35-51.

Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors
Pajtler K, Tippelt S, Siegler N, Reichling S, Zimmermann M, Mikasch R, Bode U, Gnekow A, Pietsch T, Benesch M, Rutkowski S, Fleischhack G
J NEURO-ONCOL. 2016;128(3):463-71.

Reply to letter that comments on 'Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy'
Pompe R, von Bueren A, Mynarek M, von Hoff K, Rutkowski S
EUR J CANCER. 2016;56:181-2.

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis
Ramaswamy V, Hielscher T, Mack S, Lassaletta A, Lin T, Pajtler K, Jones D, Luu B, Cavalli F, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon R, Lipp E, Dunham C, Hukin J, Eisenstat D, Fulton D, van Landeghem F, Santi M, van Veelen M, Van Meir E, Osuka S, Fan X, Muraszko K, Tirapelli D, Oba-Shinjo S, Marie S, Carlotti C, Lee J, Rao A, Giannini C, Faria C, Nunes S, Mora J, Hamilton R, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian R, Olson J, Leonard J, Gardner C, Grajkowska W, Chambless L, Cain J, Eberhart C, Ahsan S, Massimino M, Giangaspero F, Buttarelli F, Packer R, Emery L, Yong W, Soto H, Liau L, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis M, Zagzag D, Wheeler H, von Hoff K, Alonso M, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan J, Guzman M, Elbabaa S, Colman H, Dhall G, Fisher P, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro A, Pollack I, Prados M, Robins H, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins C, Rutka J, Dirks P, Pfister S, Merchant T, Gilbert M, Armstrong T, Korshunov A, Ellison D, Taylor M
J CLIN ONCOL. 2016;34(21):2468-77.

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford S, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott P, Gajjar A, Robinson G, Padovani L, André N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister S, Taylor M, Pomeroy S
ACTA NEUROPATHOL. 2016;131(6):821-31.

Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study
Sabel M, Fleischhack G, Tippelt S, Gustafsson G, Doz F, Kortmann R, Massimino M, Navajas A, von Hoff K, Rutkowski S, Warmuth-Metz M, Clifford S, Pietsch T, Pizer B, Lannering B
J NEURO-ONCOL. 2016;129(3):515-24.

New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Sturm D, Orr B, Toprak U, Hovestadt V, Jones D, Capper D, Sill M, Buchhalter I, Northcott P, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen S, Balasubramanian G, Worst B, Pajtler K, Brabetz S, Johann P, Sahm F, Reimand J, Mackay A, Carvalho D, Remke M, Phillips J, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Łastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lötsch D, Berger W, Slavc I, Haberler C, Jouvet A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley B, Schniederjan M, Santi M, Buccoliero A, Dahiya S, Kramm C, von Bueren A, von Hoff K, Rutkowski S, Herold-Mende C, Frühwald M, Milde T, Hasselblatt M, Wesseling P, Rößler J, Schüller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins V, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann M, Shalaby T, Grotzer M, van Meter T, Monoranu C, Felsberg J, Reifenberger G, Snuderl M, Forrester L, Koster J, Versteeg R, Volckmann R, van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore A, Taylor M, Jones C, Jabado N, Karajannis M, Eils R, Schlesner M, Lichter P, von Deimling A, Pfister S, Ellison D, Korshunov A, Kool M
CELL. 2016;164(5):1060-72.

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors
Torchia J, Golbourn B, Feng S, Ho K, Sin-Chan P, Vasiljevic A, Norman J, Guilhamon P, Garzia L, Agamez N, Lu M, Chan T, Picard D, de Antonellis P, Khuong-Quang D, Planello A, Zeller C, Barsyte-Lovejoy D, Lafay-Cousin L, Letourneau L, Bourgey M, Yu M, Gendoo D, Dzamba M, Barszczyk M, Medina T, Riemenschneider A, Morrissy A, Ra Y, Ramaswamy V, Remke M, Dunham C, Yip S, Ng H, Lu J, Mehta V, Albrecht S, Pimentel J, Chan J, Somers G, Faria C, Roque L, Fouladi M, Hoffman L, Moore A, Wang Y, Choi S, Hansford J, Catchpoole D, Birks D, Foreman N, Strother D, Klekner A, Bognár L, Garami M, Hauser P, Hortobágyi T, Wilson B, Hukin J, Carret A, Van Meter T, Hwang E, Gajjar A, Chiou S, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat D, Scheinemann K, Fleming A, Johnston D, Michaud J, Zelcer S, Hammond R, Afzal S, Ramsay D, Sirachainan N, Hongeng S, Larbcharoensub N, Grundy R, Lulla R, Fangusaro J, Druker H, Bartels U, Grant R, Malkin D, McGlade C, Nicolaides T, Tihan T, Phillips J, Majewski J, Montpetit A, Bourque G, Bader G, Reddy A, Gillespie G, Warmuth-Metz M, Rutkowski S, Tabori U, Lupien M, Brudno M, Schüller U, Pietsch T, Judkins A, Hawkins C, Bouffet E, Kim S, Dirks P, Taylor M, Erdreich-Epstein A, Arrowsmith C, De Carvalho D, Rutka J, Jabado N, Huang A
CANCER CELL. 2016;30(6):891-908.

Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters
von Bueren A, Kortmann R, von Hoff K, Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber N, Warmuth-Metz M, Soerensen N, Deinlein F, Benesch M, Zwiener I, Kwiecien R, Faldum A, Bode U, Fleischhack G, Hovestadt V, Kool M, Jones D, Northcott P, Kuehl J, Pfister S, Pietsch T, Rutkowski S
J CLIN ONCOL. 2016;34(34):4151-4160.

2015

Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy
Câmara-Costa H, Resch A, Kieffer V, Lalande C, Poggi G, Kennedy C, Bull K, Calaminus G, Grill J, Doz F, Rutkowski S, Massimino M, Kortmann R, Lannering B, Dellatolas G, Chevignard M
INT J RADIAT ONCOL. 2015;92(5):978-85.

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial
Clifford S, Lannering B, Schwalbe E, Hicks D, O'Toole K, Nicholson S, Goschzik T, Zur Mühlen A, Figarella-Branger D, Doz F, Rutkowski S, Gustafsson G, Pietsch T
ONCOTARGET. 2015;6(36):38827-39.

Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT Trials: clinical findings of a rare disease
Friedrich C, Warmuth-Metz M, von Bueren A, Nowak J, Bison B, von Hoff K, Pietsch T, Kortmann R, Rutkowski S
J NEUROSURG-PEDIATR. 2015;15(3):227-35.

Molecular stratification of medulloblastoma: Comparison of histological and genetic methods to detect Wnt activated tumors
Goschzik T, Zur Mühlen A, Kristiansen G, Haberler C, Stefanits H, Friedrich C, von Hoff K, Rutkowski S, Pfister S, Pietsch T
NEUROPATH APPL NEURO. 2015;41(2):135-144.

Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified
Nowak J, Seidel C, Pietsch T, Alkonyi B, Fuss T, Friedrich C, von Hoff K, Rutkowski S, Warmuth-Metz M
NEURO-ONCOLOGY. 2015;17(8):1157-65.

Neuropsychological short assessment of disease- and treatment-related intelligence deficits in children with brain tumours
Ottensmeier H, Zimolong B, Wolff J, Ehrich J, Galley N, von Hoff K, Kuehl J, Rutkowski S
EUR J PAEDIATR NEURO. 2015;19(3):298-307.

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups
Pajtler K, Witt H, Sill M, Jones D, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz H, Ryzhova M, Mack S, Ramaswamy V, Capper D, Schweizer L, Sieber L, Wittmann A, Huang Z, van Sluis P, Volckmann R, Koster J, Versteeg R, Fults D, Toledano H, Avigad S, Hoffman L, Donson A, Foreman N, Hewer E, Zitterbart K, Gilbert M, Armstrong T, Gupta N, Allen J, Karajannis M, Zagzag D, Hasselblatt M, Kulozik A, Witt O, Collins V, von Hoff K, Rutkowski S, Pietsch T, Bader G, Yaspo M, von Deimling A, Lichter P, Taylor M, Gilbertson R, Ellison D, Aldape K, Korshunov A, Kool M, Pfister S
CANCER CELL. 2015;27(5):728-43.

Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy
Pompe R, von Bueren A, Mynarek M, von Hoff K, Friedrich C, Kwiecien R, Treulieb W, Lindow C, Deinlein F, Fleischhack G, Kuehl J, Rutkowski S
EUR J CANCER. 2015;51(17):2634-2642.

Strategies to improve the quality of survival for childhood brain tumour survivors
Tallen G, Resch A, Calaminus G, Wiener A, Leiss U, Pletschko T, Friedrich C, Langer T, Grabow D, Driever P, Kortmann R, Timmermann B, Pietsch T, Warmuth-Metz M, Bison B, Thomale U, Krauss J, Mynarek M, von Hoff K, Ottensmeier H, Frühwald M, Kramm C, Temming P, Müller H, Witt O, Kordes U, Fleischhack G, Gnekow A, Rutkowski S
EUR J PAEDIATR NEURO. 2015;19(6):619-39.

Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis
Torchia J, Picard D, Lafay-Cousin L, Hawkins C, Kim S, Letourneau L, Ra Y, Ho K, Chan T, Sin-Chan P, Dunham C, Yip S, Ng H, Lu J, Albrecht S, Pimentel J, Chan J, Somers G, Zielenska M, Faria C, Roque L, Baskin B, Birks D, Foreman N, Strother D, Klekner A, Garami M, Hauser P, Hortobágyi T, Bognár L, Wilson B, Hukin J, Carret A, Van Meter T, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat D, Scheineman K, Johnston D, Michaud J, Zelcer S, Hammond R, Ramsay D, Fleming A, Lulla R, Fangusaro J, Sirachainan N, Larbcharoensub N, Hongeng S, Barakzai M, Montpetit A, Stephens D, Grundy R, Schüller U, Nicolaides T, Tihan T, Phillips J, Taylor M, Rutka J, Dirks P, Bader G, Warmuth-Metz M, Rutkowski S, Pietsch T, Judkins A, Jabado N, Bouffet E, Huang A
LANCET ONCOL. 2015;16(5):569-82.

Incidence, Trends, and Survival of Children With Embryonal Tumors
Tulla M, Berthold F, Graf N, Rutkowski S, von Schweinitz D, Spix C, Kaatsch P
PEDIATRICS. 2015;136(3):e623-32.

Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol
von Bueren A, Friedrich C, von Hoff K, Kwiecien R, Müller K, Pietsch T, Warmuth-Metz M, Hau P, Benesch M, Kuehl J, Kortmann R, Rutkowski S
EUR J CANCER. 2015;51(16):2434-43.

2014

Treatment of recurrent primitive neuroectodermal tumors (PNET) in children and adolescents with high-dose chemotherapy (HDC) and stem cell Support: results of the HITREZ 97 multicentre trial
Bode U, Zimmermann M, Moser O, Rutkowski S, Warmuth-Metz M, Pietsch T, Kortmann R, Faldum A, Fleischhack G
J NEURO-ONCOL. 2014;120(3):635-42.

Adults with CNS primitive neuroectodermal tumors/pineoblastomas: results of multimodal treatment according to the pediatric HIT 2000 protocol
Friedrich C, Müller K, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Gerber N, Hau P, Kuehl J, Kortmann R, von Bueren A, Rutkowski S
J NEURO-ONCOL. 2014;116(3):567-575.

Recent developments and current concepts in medulloblastoma
Gerber N, Mynarek M, von Hoff K, Friedrich C, Resch A, Rutkowski S
CANCER TREAT REV. 2014;40(3):356-365.

Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy
Gerber N, von Hoff K, Resch A, Ottensmeier H, Kwiecien R, Faldum A, Matuschek C, Hornung D, Bremer M, Benesch M, Pietsch T, Warmuth-Metz M, Kuehl J, Rutkowski S, Kortmann R
INT J RADIAT ONCOL. 2014;89(4):863-71.

MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system
Gessi M, von Bueren A, Treszl A, Mühlen A, Hartmann W, Warmuth-Metz M, Rutkowski S, Pietsch T
NEURO-ONCOLOGY. 2014;16(7):924-932.

Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group
Gottardo N, Hansford J, McGlade J, Alvaro F, Ashley D, Bailey S, Baker D, Bourdeaut F, Cho Y, Clay M, Clifford S, Cohn R, Cole C, Dallas P, Downie P, Doz F, Ellison D, Endersby R, Fisher P, Hassall T, Heath J, Hii H, Jones D, Junckerstorff R, Kellie S, Kool M, Kotecha R, Lichter P, Laughton S, Lee S, McCowage G, Northcott P, Olson J, Packer R, Pfister S, Pietsch T, Pizer B, Pomeroy S, Remke M, Robinson G, Rutkowski S, Schoep T, Shelat A, Stewart C, Sullivan M, Taylor M, Wainwright B, Walwyn T, Weiss W, Williamson D, Gajjar A
ACTA NEUROPATHOL. 2014;127(2):189-201.

Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing
Hovestadt V, Jones D, Picelli S, Wang W, Kool M, Northcott P, Sultan M, Stachurski K, Ryzhova M, Warnatz H, Ralser M, Brun S, Bunt J, Jäger N, Kleinheinz K, Erkek S, Weber U, Bartholomae C, von Kalle C, Lawerenz C, Eils J, Koster J, Versteeg R, Milde T, Witt O, Schmidt S, Wolf S, Pietsch T, Rutkowski S, Scheurlen W, Taylor M, Brors B, Felsberg J, Reifenberger G, Borkhardt A, Lehrach H, Wechsler-Reya R, Eils R, Yaspo M, Landgraf P, Korshunov A, Zapatka M, Radlwimmer B, Pfister S, Lichter P
NATURE. 2014;510(7506):537-541.

Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma
Kennedy C, Bull K, Chevignard M, Culliford D, Dörr H, Doz F, Kortmann R, Lannering B, Massimino M, Navajas Gutiérrez A, Rutkowski S, Spoudeas H, Calaminus G
INT J RADIAT ONCOL. 2014;88(2):292-300.

Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies
Müller K, Mynarek M, Zwiener I, Siegler N, Zimmermann M, Christiansen H, Budach W, Henke G, Warmuth-Metz M, Pietsch T, von Hoff K, von Bueren A, Bode U, Rutkowski S, Kortmann R, Fleischhack G, Tippelt S
INT J RADIAT ONCOL. 2014;88(5):1019-1024.

Hochrisiko-Medulloblastom: Erfahrungen aus HIT2000
Mynarek M, von Hoff K, Kortmann R, Rutkowski S
2014. Klinische Pädiatrie. .

Medulloblastom mit niedrigem Risiko oder Standardrisiko: Die Studien PNET4 und PNET5
Mynarek M, von Hoff K, Kortmann R, Rutkowski S
2014. Klinische Pädiatrie. .

Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma
Northcott P, Lee C, Zichner T, Stütz A, Erkek S, Kawauchi D, Shih D, Hovestadt V, Zapatka M, Sturm D, Jones D, Kool M, Remke M, Cavalli F, Zuyderduyn S, Bader G, VandenBerg S, Esparza L, Ryzhova M, Wang W, Wittmann A, Stark S, Sieber L, Seker-Cin H, Linke L, Kratochwil F, Jäger N, Buchhalter I, Imbusch C, Zipprich G, Raeder B, Schmidt S, Diessl N, Wolf S, Wiemann S, Brors B, Lawerenz C, Eils J, Warnatz H, Risch T, Yaspo M, Weber U, Bartholomae C, von Kalle C, Turányi E, Hauser P, Sanden E, Darabi A, Siesjö P, Sterba J, Zitterbart K, Sumerauer D, van Sluis P, Versteeg R, Volckmann R, Koster J, Schuhmann M, Ebinger M, Grimes H, Robinson G, Gajjar A, Mynarek M, von Hoff K, Rutkowski S, Pietsch T, Scheurlen W, Felsberg J, Reifenberger G, Kulozik A, von Deimling A, Witt O, Eils R, Gilbertson R, Korshunov A, Taylor M, Lichter P, Korbel J, Wechsler-Reya R, Pfister S
NATURE. 2014;511(7510):428-434.

Hypertrophic olivary degeneration with gadolinium enhancement after posterior fossa surgery in a child with medulloblastoma
Nowak J, Alkonyi B, Rutkowski S, Homola G, Warmuth-Metz M
CHILD NERV SYST. 2014;30(5):959-62.

MRI Characteristics of Ependymoblastoma: Results from 22 Centrally Reviewed Cases
Nowak J, Seidel C, Berg F, Pietsch T, Friedrich C, von Hoff K, Rutkowski S, Warmuth-Metz M
AM J NEURORADIOL. 2014;35(10):1996-2001.

Ependymoblastoma of the brainstem: MRI findings and differential diagnosis
Nowak J, Seidel C, Pietsch T, Friedrich C, von Hoff K, Rutkowski S, Warmuth-Metz M
PEDIATR BLOOD CANCER. 2014;61(6):1132-1134.

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort
Pietsch T, Schmidt R, Remke M, Korshunov A, Hovestadt V, Jones D, Felsberg J, Kaulich K, Goschzik T, Kool M, Northcott P, von Hoff K, von Bueren A, Friedrich C, Mynarek M, Skladny H, Fleischhack G, Taylor M, Cremer F, Lichter P, Faldum A, Reifenberger G, Rutkowski S, Pfister S
ACTA NEUROPATHOL. 2014;128(1):137-149.

Neuroonkologie
Rutkowski S, Hornung D, Kordes U, Kammler G, Hagel C, Löbel U, Ebinger M, Rössler J, Resch A, Linhart D
2014. Neuropädiatrie - Evidenzbasierte Therapie. Korinthenberg R, Panteliadis C, Hagel C (Hrsg.). 2. Aufl. München: Elsevier, .

Feasibility of intensive multimodal therapy in infants affected by rhabdoid tumors - experience of the EU-RHAB registry
Seeringer A, Bartelheim K, Kerl K, Hasselblatt M, Leuschner I, Rutkowski S, Timmermann B, Kortmann R, Koscielniak E, Schneppenheim R, Warmuth-Metz M, Gerß J, Siebert R, Graf N, Boos J, Frühwald M
KLIN PADIATR. 2014;226(3):143-148.

Cytogenetic prognostication within medulloblastoma subgroups
Shih D, Northcott P, Remke M, Korshunov A, Ramaswamy V, Kool M, Luu B, Yao Y, Wang X, Dubuc A, Garzia L, Peacock J, Mack S, Wu X, Rolider A, Morrissy A, Cavalli F, Jones D, Zitterbart K, Faria C, Schüller U, Kren L, Kumabe T, Tominaga T, Shin Ra Y, Garami M, Hauser P, Chan J, Robinson S, Bognár L, Klekner A, Saad A, Liau L, Albrecht S, Fontebasso A, Cinalli G, De Antonellis P, Zollo M, Cooper M, Thompson R, Bailey S, Lindsey J, Di Rocco C, Massimi L, Michiels E, Scherer S, Phillips J, Gupta N, Fan X, Muraszko K, Vibhakar R, Eberhart C, Fouladi M, Lach B, Jung S, Wechsler-Reya R, Fèvre-Montange M, Jouvet A, Jabado N, Pollack I, Weiss W, Lee J, Cho B, Kim S, Wang K, Leonard J, Rubin J, de Torres C, Lavarino C, Mora J, Cho Y, Tabori U, Olson J, Gajjar A, Packer R, Rutkowski S, Pomeroy S, French P, Kloosterhof N, Kros J, Van Meir E, Clifford S, Bourdeaut F, Delattre O, Doz F, Hawkins C, Malkin D, Grajkowska W, Perek-Polnik M, Bouffet E, Rutka J, Pfister S, Taylor M
J CLIN ONCOL. 2014;32(9):886-896.

Risikoadaptierte Behandlung von intrakraniellen Ependymomen: Ergebnisse von HIT2000 und Ausblick auf SIOP-Ependymoma II
von Hoff K, Mynarek M, Kortmann R, Rutkowski S
2014. Klinische Pädiatrie. .

Subgroup-specific localization of human medulloblastoma based on pre-operative MRI
Wefers A, Warmuth-Metz M, Pöschl J, von Bueren A, Monoranu C, Seelos K, Peraud A, Tonn J, Koch A, Pietsch T, Herold-Mende C, Mawrin C, Schouten-van Meeteren A, van Vuurden D, von Hoff K, Rutkowski S, Pfister S, Kool M, Schüller U
ACTA NEUROPATHOL. 2014;127(6):931-3.

WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma
Zhukova N, Ramaswamy V, Remke M, Martin D, Castelo-Branco P, Zhang C, Fraser M, Tse K, Poon R, Shih D, Baskin B, Ray P, Bouffet E, Dirks P, von Bueren A, Pfaff E, Korshunov A, Jones D, Northcott P, Kool M, Pugh T, Pomeroy S, Cho Y, Pietsch T, Gessi M, Rutkowski S, Bognár L, Cho B, Eberhart C, Conter C, Fouladi M, French P, Grajkowska W, Gupta N, Hauser P, Jabado N, Vasiljevic A, Jung S, Kim S, Klekner A, Kumabe T, Lach B, Leonard J, Liau L, Massimi L, Pollack I, Ra Y, Rubin J, Van Meir E, Wang K, Weiss W, Zitterbart K, Bristow R, Alman B, Hawkins C, Malkin D, Clifford S, Pfister S, Taylor M, Tabori U
ACTA NEUROPATHOL COM. 2014;2:174.

2013

Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups
Benesch M, von Bueren A, Dantonello T, von Hoff K, Pietsch T, Leuschner I, Claviez A, Bierbach U, Kropshofer G, Korinthenberg R, Graf N, Suttorp M, Kortmann R, Friedrich C, von der Weid N, Kaatsch P, Klingebiel T, Koscielniak E, Rutkowski S
J NEURO-ONCOL. 2013;111(3):337-345.

Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy.
Friedrich C, von Bueren A, von Hoff K, Gerber N, Ottensmeier H, Deinlein F, Benesch M, Kwiecien R, Pietsch T, Warmuth-Metz M, Faldum A, Kuehl J, Kortmann R, Rutkowski S
NEURO-ONCOLOGY. 2013;15(2):224-234.

Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study
Friedrich C, von Bueren A, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Hau P, Deinlein F, Kuehl J, Kortmann R, Rutkowski S
EUR J CANCER. 2013;49(4):893-903.

Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays
Hovestadt V, Remke M, Kool M, Pietsch T, Northcott P, Fischer R, Cavalli F, Ramaswamy V, Zapatka M, Reifenberger G, Rutkowski S, Schick M, Bewerunge-Hudler M, Korshunov A, Lichter P, Taylor M, Pfister S, Jones D
ACTA NEUROPATHOL. 2013;125(6):913-6.

What's in a name? Intracranial peripheral primitive neuroectodermal tumors and CNS primitive neuroectodermal tumors are not the same
Müller K, Diez B, Muggeri A, Pietsch T, Friedrich C, Rutkowski S, von Hoff K, von Bueren A, Zwiener I, Bruns F
STRAHLENTHER ONKOL. 2013;189(5):372-9.

Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma
Remke M, Hering E, Gerber N, Kool M, Sturm D, Rickert C, Gerß J, Schulz S, Hielscher T, Hasselblatt M, Jeibmann A, Hans V, Ramaswamy V, Taylor M, Pietsch T, Rutkowski S, Korshunov A, Monoranu C, Frühwald M
CHILD NERV SYST. 2013;29(8):1253-62.

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
Remke M, Ramaswamy V, Peacock J, Shih D, Koelsche C, Northcott P, Hill N, Cavalli F, Kool M, Wang X, Mack S, Barszczyk M, Morrissy A, Wu X, Agnihotri S, Luu B, Jones D, Garzia L, Dubuc A, Zhukova N, Vanner R, Kros J, French P, Van Meir E, Vibhakar R, Zitterbart K, Chan J, Bognár L, Klekner A, Lach B, Jung S, Saad A, Liau L, Albrecht S, Zollo M, Cooper M, Thompson R, Delattre O, Bourdeaut F, Doz F, Garami M, Hauser P, Carlotti C, Van Meter T, Massimi L, Fults D, Pomeroy S, Kumabe T, Ra Y, Leonard J, Elbabaa S, Mora J, Rubin J, Cho Y, McLendon R, Bigner D, Eberhart C, Fouladi M, Wechsler-Reya R, Faria C, Croul S, Huang A, Bouffet E, Hawkins C, Dirks P, Weiss W, Schüller U, Pollack I, Rutkowski S, Meyronet D, Jouvet A, Fèvre-Montange M, Jabado N, Perek-Polnik M, Grajkowska W, Kim S, Rutka J, Malkin D, Tabori U, Pfister S, Korshunov A, von Deimling A, Taylor M
ACTA NEUROPATHOL. 2013;126(6):917-29.

Effective childhood cancer Treatment: the impact of large scale clinical trials in Germany and Austria
Rossig C, Juergens H, Schrappe M, Moericke A, Henze G, von Stackelberg A, Reinhardt D, Burkhardt B, Woessmann W, Zimmermann M, Gadner H, Mann G, Schellong G, Mauz-Koerholz C, Dirksen U, Bielack S, Berthold F, Graf N, Rutkowski S, Calaminus G, Kaatsch P, Creutzig U
PEDIATR BLOOD CANCER. 2013;60(10):1574-81.

A very rare cancer in Down Syndrome: medulloblastoma. Epidemiological data from 13 countries
Satgé D, Stiller C, Rutkowski S, von Bueren A, Lacour B, Sommelet D, Nishi M, Massimino M, Garré M, Moreno F, Hasle H, Jakab Z, Greenberg M, von der Weid N, Kuehni C, Zurriaga O, Vicente M, Peris-Bonet R, Benesch M, Vekemans M, Sullivan S, Rickert C
J NEURO-ONCOL. 2013;112(1):107-14.

Infantile malignant brain tumors
von Hoff K, Rutkowski S
2013. Tumors of the pediatric central nervous system. Keating R, Tait Goodrich J, Packer R (Hrsg.). 2.. Aufl. New York: Georg Thieme Verlag KG, .

Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group
Warren K, Poussaint T, Vezina G, Hargrave D, Packer R, Goldman S, Wen P, Pollack I, Zurakowski D, Kun L, Prados M, Rutkowski S, Kieran M
PEDIATR BLOOD CANCER. 2013;60(9):1397-401.

Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih D, Martin D, Castelo-Branco P, Baskin B, Ray P, Bouffet E, von Bueren A, Jones D, Northcott P, Kool M, Sturm D, Pugh T, Pomeroy S, Cho Y, Pietsch T, Gessi M, Rutkowski S, Bognar L, Klekner A, Cho B, Kim S, Wang K, Eberhart C, Fevre-Montange M, Fouladi M, French P, Kros M, Grajkowska W, Gupta N, Weiss W, Hauser P, Jabado N, Jouvet A, Jung S, Kumabe T, Lach B, Leonard J, Rubin J, Liau L, Massimi L, Pollack I, Shin Ra Y, Van Meir E, Zitterbart K, Schüller U, Hill R, Lindsey J, Schwalbe E, Bailey S, Ellison D, Hawkins C, Malkin D, Clifford S, Korshunov A, Pfister S, Taylor M, Tabori U
J CLIN ONCOL. 2013;31(23):2927-35.

2012

Proper cerebellar development requires expression of β1-integrin in Bergmann glia, but not in granule neurons.
Frick A, Grammel D, Schmidt F, Pöschl J, Priller M, Pagella P, von Bueren A, André O, Peraud A, Tonn J, Rutkowski S, Rutkowski S, Kretzschmar H, Schüller U
GLIA. 2012;60(5):820-832.

A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma.
Gerber N, von Hoff K, von Bueren A, Treulieb W, Treulieb W, Deinlein F, Benesch M, Zwiener I, Soerensen N, Warmuth-Metz M, Pietsch T, Mittler U, Kuehl J, Kortmann R, Rutkowski S, Rutkowski S
EUR J CANCER. 2012;48(13):2028-2036.

p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease.
Gessi M, von Bueren A, Rutkowski S, Rutkowski S, Pietsch T
J NEURO-ONCOL. 2012;106(1):135-141.

Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem.
Grammel D, Warmuth-Metz M, von Bueren A, André O, Kool M, Pietsch T, Kretzschmar H, Rutkowski S, Rutkowski S, Pfister S, Schüller U
ACTA NEUROPATHOL. 2012;123(4):601-614.

Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature.
Grunewald T, Greulich N, Kontny U, Frühwald M, Rutkowski S, Kordes U, Scheurlen W, Schmidt W, Stachel D, Metzler M, Mittler U, Graf N, Benesch M, Burdach S
KLIN PADIATR. 2012;224(3):124-131.

Dissecting the genomic complexity underlying medulloblastoma.
Jones D, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho Y, Pugh T, Hovestadt V, Stütz A, Rausch T, Warnatz H, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber U, Wang Q, Lasitschka B, Bartholomae C, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts M, Russell R, Coco S, Tonini G, Schüller U, Hans V, Graf N, Kim Y, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik A, von Deimling A, Witt O, Maass E, Rössler J, Ebinger M, Schuhmann M, Frühwald M, Hasselblatt M, Jabado N, Rutkowski S, von Bueren A, André O, Williamson D, Clifford S, McCabe M, Collins V, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott P, Taylor M, Meyerson M, Pomeroy S, Yaspo M, Korbel J, Korshunov A, Eils R, Pfister S, Lichter P
NATURE. 2012;488(7409):100-105.

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
Kool M, Korshunov A, Remke M, Jones D, Schlanstein M, Northcott P, Cho Y, Koster J, Antoinette S, van Vuurden D, Clifford S, Pietsch T, von Bueren A, Rutkowski S, Rutkowski S, McCabe M, Collins V, Bäcklund M, Haberler C, Bourdeaut F, Delattre O, Doz F, Ellison D, Gilbertson R, Pomeroy S, Taylor M, Lichter P, Pfister S
ACTA NEUROPATHOL. 2012;123(4):473-484.

Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.
Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Björk-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford S, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R
J CLIN ONCOL. 2012;30(26):3187-3193.

Molecular subgroups of medulloblastoma: the current consensus.
Taylor M, Northcott P, Korshunov A, Remke M, Cho Y, Clifford S, Eberhart C, Parsons D, Rutkowski S, Gajjar A, Ellison D, Lichter P, Gilbertson R, Pomeroy S, Kool M, Pfister S
ACTA NEUROPATHOL. 2012;123(4):465-472.

DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis.
von Bueren A, André O, Hagel C, Hagel C, Cai H, Remke M, Hasselblatt M, Feuerstein B, Pernet S, Delattre O, Rutkowski S, Rutkowski S, Pfister S, Baudis M
J NEURO-ONCOL. 2012;109(2):415-423.

Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
von Bueren A, Bacolod M, Hagel C, Heinimann K, Fedier A, Kordes U, Pietsch T, Koster J, Grotzer M, Friedman H, Marra G, Kool M, Rutkowski S
BRIT J CANCER. 2012;107(8):1399-1408.

Medulloblastoma.
von Hoff K, Rutkowski S
CURR TREAT OPTION NE. 2012;14(4):416-426.

2011

Primary central nervous system primitive neuroectodermal tumors (CNS-PNETs) of the spinal cord in children: four cases from the German HIT database with a critical review of the literature.
Benesch M, Sperl D, von Bueren A, André O, von Hoff K, von Hoff K, Warmuth-Metz M, Ferrari R, Lassay L, Kortmann R, Rutkowski S, Rutkowski S
J NEURO-ONCOL. 2011;104(1):279-286.

Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006.
Gerber N, von Hoff K, von Bueren A, Treulieb W, Treulieb W, Warmuth-Metz M, Pietsch T, Soerensen N, Faldum A, Emser A, Schlegel P, Deinlein F, Rutkowski S, Rutkowski S
J NEURO-ONCOL. 2011;102(3):459-469.

Ectopic craniopharyngioma.
Kordes U, Flitsch J, Hagel C, Goebell E, Schwarz R, Herberhold T, von Bueren A, Rutkowski S, Müller H
KLIN PADIATR. 2011;223(3):176-177.

Childhood medulloblastoma.
Massimino M, Giangaspero F, Garrè M, Gandola L, Poggi G, Biassoni V, Gatta G, Rutkowski S
CRIT REV ONCOL HEMAT. 2011;79(41):65-83.

Curative treatment for central nervous system medulloepithelioma despite residual disease after resection. Report of two cases treated according to the GPHO Protocol HIT 2000 and review of the literature.
Müller K, Zwiener I, Welker H, Maass E, Bongartz R, Berthold F, Pietsch T, Warmuth-Metz M, von Bueren A, Rutkowski S
STRAHLENTHER ONKOL. 2011;187(11):757-762.

The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
Oehler C, von Bueren A, André O, Furmanova P, Broggini-Tenzer A, Rutkowski S, Rutkowski S, Frei K, Grotzer M, Pruschy M
NEURO-ONCOLOGY. 2011;13(9):1000-1010.

Expression of BARHL1 in medulloblastoma is associated with prolonged survival in mice and humans.
Pöschl J, Lorenz A, Hartmann W, von Bueren A, Kool M, Li S, Peraud A, Tonn J, Herms J, Xiang M, Rutkowski S, Kretzschmar H, Schüller U
ONCOGENE. 2011;30(47):4721-4730.

Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients
Priller M, Pöschl J, Abrão L, von Bueren A, Cho Y, Rutkowski S, Kretzschmar H, Schüller U
CLIN CANCER RES. 2011;17(21):6791-801.

FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Remke M, Hielscher T, Korshunov A, Northcott P, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schöttler A, von Bueren A, André O, Rutkowski S, Rutkowski S, Scheurlen W, Kulozik A, Taylor M, Lichter P, Pfister S
J CLIN ONCOL. 2011;29(29):3852-3861.

c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients.
von Bueren A, André O, Oehler C, von Hoff K, von Hoff K, Pruschy M, Seifert B, Gerber N, Warmuth-Metz M, Stearns D, Eberhart C, Rutkowski S, Rutkowski S, Grotzer M
BMC CANCER. 2011;11:74.

Late complete remission of supratentorial primitive neuroectodermal tumor (CNS-PNET) after multiple relapses.
von Bueren A, André O, Warmuth-Metz M, Schlegel P, Soerensen N, Krauss J, Roggendorf W, Pietsch T, Feiden W, Graf N, Pohl F, Flentje M, Rutkowski S, Rutkowski S
PEDIATR BLOOD CANCER. 2011;56(3):503-505.

Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.
von Bueren A, von Hoff K, von Hoff K, Pietsch T, Gerber N, Warmuth-Metz M, Deinlein F, Zwiener I, Faldum A, Fleischhack G, Benesch M, Krauss J, Kuehl J, Rutkowski S, Rutkowski S
NEURO-ONCOLOGY. 2011;13(6):669-679.

Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database.
von Hoff K, Hinkes B, Dannenmann-Stern E, von Bueren A, André O, Warmuth-Metz M, Soerensen N, Emser A, Zwiener I, Schlegel P, Kuehl J, Frühwald M, Kortmann R, Rutkowski S, Rutkowski S
PEDIATR BLOOD CANCER. 2011;57(6):978-985.

Recurrence in childhood medulloblastoma.
Warmuth-Metz M, Blashofer S, von Bueren A, von Hoff K, von Hoff K, Bison B, Pohl F, Kortmann R, Rutkowski S, Rutkowski S
J NEURO-ONCOL. 2011;103(3):705-711.

High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D Pilot study.
Wolff J, Kortmann R, Wolff B, Pietsch T, Peters O, Schmid H, Rutkowski S, Warmuth-Metz M, Kramm C
J NEURO-ONCOL. 2011;102(3):433-442.

2010

Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours.
Ardon H, Steven D, Frank V, Claes L, Kramm C, Rutkowski S, Wolff J, Gool V, Stefaan W
PEDIATR BLOOD CANCER. 2010;54(4):519-525.

Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database.
Benesch M, Weber-Mzell D, Gerber N, von Hoff K, Deinlein F, Krauss J, Warmuth-Metz M, Kortmann R, Pietsch T, Driever P, Quehenberger F, Urban C, Rutkowski S
J NEUROSURG-PEDIATR. 2010;6(2):137-144.

Non-cerebellar primitive neuroectodermal tumors (PNET): summary of the Milan consensus and state of the art workshop on marrow ablative chemotherapy with hematopoietic cell rescue for malignant brain tumors of childhood and adolescents.
Fangusaro J, Massimino M, Rutkowski S, Gururangan S
PEDIATR BLOOD CANCER. 2010;54(4):638-640.

Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schöttler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik A, von Deimling A, Lichter P, Pfister S
J CLIN ONCOL. 2010;28(18):3054-3060.

TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E, Remke M, Sturm D, Benner A, Witt H, Till M, von Bueren A, André O, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik A, Witt O, Scheurlen W, Rutkowski S, Rutkowski S, Taylor M, Tabori U, Lichter P, Korshunov A, Pfister S
J CLIN ONCOL. 2010;28(35):5188-5196.

Medulloblastoma in young children.
Rutkowski S, Cohen B, Finlay J, Luksch R, Ridola V, Valteau-Couanet D, Hara J, Garre M, Grill J
PEDIATR BLOOD CANCER. 2010;54(4):635-637.

Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis.
Rutkowski S, von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, Giangaspero F, Ellison D, Garre M, Biassoni V, Grundy R, Finlay J, Dhall G, Raquin M, Grill J
J CLIN ONCOL. 2010;28(33):4961-4968.

Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
von Hoff K, Hartmann W, von Bueren A, Oscar A, Gerber N, Grotzer M, Rutkowski S, Rutkowski S
PEDIATR BLOOD CANCER. 2010;54(3):369-376.

Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol.
Wolff J, Driever P, Erdlenbruch B, Kortmann R, Rutkowski S, Pietsch T, Parker C, Metz M, Gnekow A, Kramm C
CANCER-AM CANCER SOC. 2010;116(3):705-712.

2009

Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy
Rutkowski S, Gerber N, von Hoff K, Gnekow A, Bode U, Graf N, Berthold F, Henze G, Wolff J, Warmuth-Metz M, Soerensen N, Emser A, Ottensmeier H, Deinlein F, Schlegel P, Kortmann R, Pietsch T, Kuehl J
NEURO-ONCOLOGY. 2009;11(2):201-10.

Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91
von Hoff K, Hinkes B, Gerber N, Deinlein F, Mittler U, Urban C, Benesch M, Warmuth-Metz M, Soerensen N, Zwiener I, Goette H, Schlegel P, Pietsch T, Kortmann R, Kuehl J, Rutkowski S
EUR J CANCER. 2009;45(7):1209-17.

2007

Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91
Hinkes B, von Hoff K, Deinlein F, Warmuth-Metz M, Soerensen N, Timmermann B, Mittler U, Urban C, Bode U, Pietsch T, Schlegel P, Kortmann R, Kuehl J, Rutkowski S
J NEURO-ONCOL. 2007;81(2):217-23.

Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas
Pfister S, Remke M, Toedt G, Werft W, Benner A, Mendrzyk F, Wittmann A, Devens F, von Hoff K, Rutkowski S, Kulozik A, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A
GENE CHROMOSOME CANC. 2007;46(9):839-51.

Letzte Aktualisierung aus dem FIS: 28.03.2024 - 00:47 Uhr